Diplomat Pharmacy (NYSE:DPLO) updated its FY 2019 earnings guidance on Friday. The company provided earnings per share guidance of $-0.5-0.34 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.61. The company issued revenue guidance of $4.7-5 billion, compared to the consensus revenue estimate of $5.45 billion.Diplomat Pharmacy also updated its FY19 guidance to ($0.50-0.34) EPS.
Several analysts have recently commented on the company. Zacks Investment Research cut Diplomat Pharmacy from a hold rating to a strong sell rating in a report on Tuesday, November 27th. JPMorgan Chase & Co. cut Diplomat Pharmacy from an overweight rating to a neutral rating and decreased their target price for the stock from $9.00 to $8.00 in a report on Friday, February 22nd. Barclays restated an overweight rating and set a $8.00 target price (down previously from $18.00) on shares of Diplomat Pharmacy in a report on Monday, February 25th. Leerink Swann cut Diplomat Pharmacy from an outperform rating to a market perform rating and set a $30.00 target price on the stock. in a report on Monday, February 25th. Finally, Lake Street Capital cut Diplomat Pharmacy from a buy rating to a hold rating and decreased their target price for the stock from $30.00 to $15.00 in a report on Tuesday, January 8th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus target price of $13.78.
Diplomat Pharmacy stock opened at $5.34 on Friday. The stock has a market capitalization of $485.54 million, a P/E ratio of 6.36 and a beta of 0.74. Diplomat Pharmacy has a 12-month low of $5.56 and a 12-month high of $28.74. The company has a current ratio of 0.95, a quick ratio of 0.66 and a debt-to-equity ratio of 0.58.
WARNING: This report was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2019/03/15/diplomat-pharmacy-dplo-updates-fy-2019-earnings-guidance.html.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Read More: 12b-1 Fees
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.